Advancing Alzheimer’s and Parkinson’s R&D

With persistent challenges still dominating Alzheimer’s and Parkinson’s drug development, how can pharmaceutical manufacturers push new research boundaries? Difficulties with early disease detection, suboptimal trial designs, and the complexity of neurodegenerative pathologies that have historically led to high failure rates remain. This free whitepaper explores the latest breakthroughs in screening methodologies, biomarker integration, and adaptive clinical trial designs, offering insights from a global survey of 129 CNS therapeutic developers. Learn how advancements in digital health technologies, decentralised trial models, and AI-driven biomarker strategies are reshaping neurodegenerative R&D. Fill in your details to find out more.